 Int J Gynecol Obstet 2017; 138 (Suppl. 1): 47–56
wileyonlinelibrary.com/journal/ijgo | 47
DOI: 10.1002/ijgo.12184
S U P P L E M E N T  A R T I C L E
The health and economic impact of scaling cervical cancer 
prevention in 50 low- 
 and lower- 
middle- 
income countries
Nicole G. Campos1,* | Monisha Sharma2 | Andrew Clark3 | Kyueun Lee4 | Fangli Geng1 |  
Catherine Regan1 | Jane Kim1 | Stephen Resch1
1Department of Health Policy and 
Management, Center for Health Decision 
Science, Harvard T.H. Chan School of Public 
Health, Boston, MA, USA
2Department of Epidemiology, School of 
Public Health, University of Washington 
Seattle,Seattle,WA,USA
3Department of Health Services Research and 
Policy, London School of Hygiene and Tropical 
Medicine, London, UK
4Department of Health Research and 
Policy, Stanford University, Stanford, CA, USA
*Correspondence
Nicole G. Campos, Center for Health Decision 
Science, Department of Health Policy and 
Management, Harvard T.H. Chan School of 
Public Health, Boston, MA, USA.
Email: ncampos@hsph.harvard.edu
Abstract
Objective: Toestimatethehealthimpact,financialcosts,andcost-
effectivenessof
scaling-
upcoverageofhumanpapillomavirus(HPV)vaccination(younggirls)andcer-
vical cancer screening (women of screening age) for women in countries that will likely 
need donor assistance.
Methods: Weusedamodel-
basedapproachtosynthesizepopulation,demographic,
andepidemiologicaldatafrom50low-
andlower-
middle-
incomecountries.Models
wereusedtoprojectthecosts(US$),lifetimehealthimpact(cervicalcancercases,
deathsaverted),andcost-
effectiveness(US$perdisabilityadjustedlifeyear[DALY]
averted)of:(1)two-
doseHPV-
16/18vaccinationofgirlsaged10years;(2)once-
in-
a-
lifetimescreening,withtreatmentwhenneeded,ofwomenaged35yearswitheither
HPVDNAtestingorvisualinspectionwithaceticacid(VIA);and(3)cervicalcancer
treatmentovera10-
yearroll-
out.
Results: WeestimatedthatbothHPVvaccinationandscreeningwouldbeverycost-
effective, and a comprehensive program could avert 5.2 million cases, 3.7 million
deaths,and22.0millionDALYsoverthelifetimesoftheinterventioncohortsfora
total10-
yearprogramcostofUS$3.2billion.
Conclusion: InvestmentinHPVvaccinationofyounggirlsandcervicalcancerscreen-
and-
treatprogramsinlow-
andlower-
middle-
incomecountriescouldavertasubstan-
tialburdenofdiseasewhileprovidinggoodvalueforpublichealthdollars.
K E Y W O R D S
Cancerscreening;Cost-effectivenessanalysis;HPV;HPVDNAtests;Uterinecervicalneoplasms
1 | INTRODUCTION
Despite the availability of both primary and secondary prevention,
anestimated528000womenworldwidedevelopedcervicalcancer
in 2012, and 266 000 died from the disease.1Primarypreventionis
available in the form of effective prophylactic vaccines against the
oncogenichumanpapillomavirus(HPV)genotypesthatcauseapprox-
imately 70% (bivalent and quadrivalent vaccines) to 90% (9-
valent
vaccine) of cervical cancers.2–5 For women beyond the target age 
ofadolescentvaccination,secondarypreventionwithscreeningcan
detect and treat precancerous lesions caused by oncogenic HPV
beforeprogressiontoinvasivecancer.Yettheseopportunitiesforpre-
ventionarenotreachingwomeninpoorcountries,where85%ofthe
cervical cancer burden resides.
TheWHOrecommendsHPVvaccinationforgirlsaged9–13years,
prior to initiation of sexual activity.6 For screening, the WHO 
ThisisanopenaccessarticleunderthetermsoftheCreativeCommonsAttributionLicense,whichpermitsuse,distributionandreproductioninanymedium,
provided the original work is properly cited.
© 2017 The Authors. International Journal of Gynecology & ObstetricspublishedbyJohnWiley&SonsLtdonbehalfofInternationalFederationofGynecologyand
Obstetrics
 48  |    
﻿Campos  ET CAL
recommends that cervical cancer screening programs should priori-
tizewomenaged30–49years,astheriskofcervicalcancerrisesafter
age30years.TheWHOrecommendationsnotethatsetting-
specific
screening intervals and frequency will depend upon availability of 
fundsandinfrastructure,andthatscreeningevenonceinalifetime—
with treatment if needed—is beneficial. While organized screening
withPapanicolaou(Pap)testinghasreducedtheincidenceofandmor-
talityattributabletocervicalcancerinmanyhigh-
incomecountries,
Paptestingislogisticallydifficultinlow-
resourcesettings.Itrequires
costlylaboratoryinfrastructureandmultiplevisitsforscreening,diag-
nosis,andtreatment.Thus,wheresufficientresourcesareavailable,
theWHOrecommendsscreeningwithHPVtestingtodetectonco-
genic infections,with prompt linkage to treatment forwomenwho
testpositive.Forsettingswithfewerresources,visualinspectionwith
aceticacid(VIA)—alesssensitivebutlow-
costtestthatinvolvesappli-
cationofaceticacid(vinegar)tothecervixtodetectabnormalities,
yieldinganimmediateresult—isrecommended,andcanbefollowed
by same-
day treatment with cryotherapy, to destroy precancerous
lesionsbyfreezing.
Duetohighvaccinepricesandthelogisticalchallengesofdeliver-
inganadolescentvaccine,roll-
outofHPVvaccinationprogramshas
beenslowinthesettingswhereitisneededmost.Inlow-
andlower-
middle-
incomecountries,where56%oftheglobalburdenofcervi-
calcancerresides,only1.0%and0.1%,respectively,offemalesaged
10–20 years had been vaccinated as of October 2014.7 Momentum 
appears to be increasing as Gavi,TheVaccineAlliance—an interna-
tionalpublic–privatepartnershipaimingtoimproveaccesstonewand
underused vaccines in 54 eligible countries8—beganacceptingappli-
cationsforHPVvaccinessupportin2012.Gavihassincenegotiated
a vaccine price of US $4.50 per dose for eligible countries,9 and 27 
countrieshavebeenapprovedforHPVvaccinedemonstrationproj-
ects.10Inaddition,theGavi-
eligiblecountriesofLesotho,Rwanda,and
UgandahaveinitiatednationalHPVvaccinationprograms.11
Scale-
upofcervicalcancerscreeningprogramsinlow-
andlower-
middle-
incomecountrieshasnot,todate,experiencedthesamefor-
wardmomentumasvaccination.ThereisonlyahandfulofHPVtesting
demonstrationprojects,andnofullyscalednationalprogramsinlow-
resourcesettings.12Whilemorelow-
andlower-
middle-
incomecoun-
tries have introducedVIA pilot programs or includeVIA in national
guidelines, coverage remains low.13
To evaluate any policy intervention, decision makers require
information on feasibility, acceptability, financing, and value for
money.Atthiscriticaljunctureforcervicalcancerpreventionefforts,
we sought to provide information to those making immunization
andscreeningpolicyrecommendations,includingtheWHO,financ-
ing mechanisms, donors, and country governments. Our objective
wastoestimate,forcountriesthatwilllikelyneeddonorassistance,
thefinancialcostsandcost-
effectivenessofscaling-
upcoverageof
HPVvaccinationforyounggirlsandcervicalcancerscreeningand
treatment of precancerous lesions for women of screening age. We 
consideredvaccinationandscreeningseparately(foreligiblegirlsand
women,respectively)duringa10-
yearinterventionperiodbetween
2017 and 2026.
2 | METHODS
2.2 | Analytic overview
We used a model-
based approach to synthesize population, demo-
graphic, and epidemiological data from 50 low- and lower-
middle-
income(LIandLMI)countrieswithpopulationsover1millionpersons
and gross national income (GNI) per capita less than or equal to
US $2585 (Supplementary material Tables S1 and S2); this represents 
the midpoint GNI per capita of the World Bank LMI country income 
tier,14 and henceforth we refer to LMI countries with a GNI per capita 
below this midpoint as “LMI1.” The Excel-
based CERVIVAC model
describedinthenextsectionwasusedtoprojectthecostsandlifetime
healthimpactof:(1)two-
doseHPV-
16/18vaccinationofgirlsaged
10years;(2)once-
in-
a-
lifetimescreening(withtreatmentifneeded)of
womenaged35yearswitheitherHPVtestingorVIA;and(3)cervical
cancertreatment.Weestimatedcountry-
specificunitcostinputsfor
theCERVIVACmodel(includingvaccinedosesandservicedelivery;
direct medical costs of screening, diagnosis, and treatment of precan-
cer; and direct medical costs of cervical cancer treatment by stage) 
from the literature, using previously described methods.15 We esti-
matedcountry-
specificepidemiologicdatainputsonburdenofHPV,
precancer, and cervical cancer by applying previously described meth-
ods,15using:(1)multivariateregressionmodelstopredictcountry-and
age-
specificHPVprevalence(SupplementarymaterialTableS3)15; (2) 
a peer-
reviewed individual-
based microsimulation model that was
previouslycalibratedtofourseparatelow-andlower-
middle-
income
countries (El Salvador, India, Nicaragua, and Uganda)16–18 to predict 
country-
specificprevalenceofprecancer15; and (3) GLOBOCAN 2012 
toinformcountry-andage-
specificcervicalcancerincidenceandmor-
tality (Supplementary material Tables S4 and S5).1 To estimate the
effectivenessofHPV-
16/18vaccination,wereliedonvaccinetrialdata
andepidemiologicdataontheproportionofcervicalcancersattributed
to HPV-
16/18.5,19–21 CERVIVAC inputs pertaining to screening and
treatmenteffectivenesswerederivedfromthemicrosimulationmodel,
whichwasusedtoestimatethereductioninage-
specificcervicalcan-
cerincidenceandmortality,aswellasshiftsinstagedistributionof
detected cervical cancer, associated with each screening strategy. We 
estimatedcurrentaccesstocancertreatmentineachcountryusing
published literature to project cervical cancer treatment cost savings 
associatedwitheachvaccinationandscreeningscenario.22
Theanalysiswasconductedfromapayerperspective.Thetime
horizonwasthelifetimeofbirthcohortswhoreceivedeithervaccina-
tionorscreeningbasedonageduringthe10-
yearinterventionperiod
(2017–2026). Because girls aged 10 years would not be subsequently 
eligibleforscreeningduringtheinterventionperiod,wedidnotexam-
ine the impact of screening in vaccinated women. We present both 
undiscounted costs and future costs discounted at an annual rate 
of3%in2013US$.Healthbenefitsarereportedascervicalcancer
cases,deaths,anddisability-
adjustedlifeyears(DALYs)averted;DALYs
have been discounted at an annual rate of 3%. We present incremental 
cost-
effectivenessratios(ICERs)—asthenetcostperDALYavertedto
accountforcancertreatmentoffsets—separatelyforvaccinationand
     |  49
﻿Campos  ET CAL
screening(relativetonointervention).Whilethereisnouniversalcri-
terionthatdefinesathresholdcost-
effectivenessratio,weconsider
theheuristicthataninterventionwithanICERlessthanGDPpercap-
itaisestimatedtobe“verycost-
effective”andlessthanthreetimes
GDPpercapitaisestimatedtobe“cost-
effective”.23
2.2 | CERVIVAC model
TheCERVIVACmodelwasdevelopedforthePanAmericanHealth
Organization’s ProVac Initiative (provac-
toolkit.com) as a tool to
enableLatinAmericaandCaribbeancountryteamstoconductlocal
cost-
effectivenessanalysisofcervicalcancerprevention.CERVIVAC
containsseparatemodulesforevaluatingthecostsandeffectiveness
associatedwithHPVvaccination,screeningandtreatmentofprecan-
cerous lesions, and cervical cancer treatment. The model, programmed 
usingMicrosoftExcelandVisualBasicforApplications2007(Microsoft
Corporation,Redmond,WA,USA),tracksmultiplebirthcohortsstart-
ing at a target age (i.e. 10years for HPV vaccination; 35years for
screening),projectingcostoutcomesbycountingresourceutilization
eventsandmultiplyingthesebyacountry-
specificunitcost.
The HPV vaccination module counts the cost of vaccine doses
and service delivery costs. The screening module counts the costs of 
screening visits, treatment with cryotherapy, and—for women inel-
igiblefor cryotherapy—colposcopyandloop electrosurgical excision
procedures (LEEP); resource utilization is driven by screening test
sensitivityandspecificity,HPVprevalence,andtheprevalenceofpre-
cancer.Thecancertreatmentmodulecountsstage-
specifictreatment
costs for local, regional, and distant cancers.
The number of females alive in each of the 50 countries, in each sin-
gleyearofage,wasbasedonthe2015UnitedNationsWorldPopulation
Prospects.24Eachbirthcohortwastrackedoveritslifetimetocapture
health service utilization, burden of disease, and long-
term health
impactofvaccinationandscreeningduringtheinterventionperiod.
2.3 | HPV vaccination and cervical cancer 
screening strategies
Scale-
upassumptionsforvaccinationandscreeningaredisplayedin
Figure1A–C.Thehealthimpactofvaccinationwascalculatedbasedon
aproportionatereductioninage-
specificcancerincidenceoverthelife-
timeofthevaccinatedcohorts,assuming93%lifelongvaccineefficacy
againstthe70%ofcervicalcancersattributabletoHPV-
16/18,5,19–21 
withnoserotypereplacementandnoherdimmunitybenefit.
The health impact of screening was based on the screening test 
anditsperformancecharacteristics(SupplementarymaterialTableS6).
Wemadethefollowingsimplifyingassumptionsacrossallcountries:
(1)VIA and HPV testingwere followed by cryotherapy for all eligi-
blewomen,whichwas90%effectiveattreatingHPVinfectionsand
underlyingprecancer;(2)aproportionofwomenwhoscreenedposi-
tiveweredeemedineligibleforimmediatecryotherapy(5%ofwomen
with no lesion and 25% of women with cervical intraepithelial neopla-
sia (CIN) 2/3) and required a colposcopy and biopsy; (3) colposcopy 
andbiopsyhad100%sensitivityandspecificityattheCIN2+thresh-
old;(4)womenwithhistologicallyconfirmedCIN2/3receivedLEEP,
whichwas100%effective.Tocapturecostsassociatedwithscreening,
diagnosis,andtreatmentofprecancer,CERVIVACestimatedthenum-
beroftruepositives(womenwithCIN2/3thatscreenedpositive)and
thenumberoffalsepositives(womenwithnolesionthatscreened
positive)basedonscreeningtestperformanceandtheprevalenceof
oncogenicHPVandCIN2/3.
FIGURE 1 Scale-
upscenariosforHPV-
16/18vaccinationofyounggirls,aged10years,andonce-
in-
a-
lifetimescreeningofwomen,aged
35years.(A)Inbothlow-
andlower-
middle-
incomecountries(withGrossNationalIncome[GNI]percapitalessthanorequaltoUS$2585),we
assumedthatHPVvaccinationcoveragewouldrolloutwithlinearincreasesof10%peryearduringthe10-
yearinterventionperiod,beginning
at10%coveragein2017andreachingfullcoverage(100%)in2026.(B)Inlower-
middle-
incomecountries(withGrossNationalIncome[GNI]
percapitabetweenUS$1046andUS$2585),weassumedthatscreeningwithbothvisualinspectionwithaceticacid(VIA)andHPVtesting
would roll out with linear increases of 10% per year for each test, beginning at 20% total screening coverage in 2017 and reaching full coverage 
(100%)in2021.WethenassumedagradualreplacementwithHPV-
basedscreening,whichreplacedVIAin10%ofthepopulationin2022
andincreasedlinearlytocover100%ofthescreening-
eligiblepopulationby2026.(C)Inlow-
incomecountries(withGrossNationalIncome
[GNI]percapitalessthanorequaltoUS$1045),weassumedthatscreeningwithvisualinspectionwithaceticacid(VIA)wouldrolloutwith
linear increases of 20% per year, beginning at 20% coverage in 2017 and reaching full coverage (100%) in 2021. We then assumed a gradual 
replacementwithHPV-
basedscreening,whichreplacedVIAin10%ofthepopulationin2022andincreasedlinearlytocover50%ofthe
screening-
eligiblepopulationby2026.[Colourfigurecanbeviewedatwileyonlinelibrary.com]
 50  |    
﻿Campos  ET CAL
For each screening test, we used the microsimulation model to
estimatepercentreductionsinage-
specificcervicalcancerincidence
andmortality(in5-
yearagegroupsfromage20toage84years)attrib-
utable to a screening program with the features described above (e.g. 
treatmenteffectiveness,eligibilityforcryotherapy,etc).Descriptionsof
thismicrosimulationmodelandtheparameterizationprocess(including
modelcalibrationtoepidemiologicdataforthedevelopmentoffour
country-
specificmodelsreflectingthenaturalhistoryofcervicalcan-
cer in El Salvador, India, Nicaragua, and Uganda) have been previously 
published.16–18Inbrief,weestimatedbaseline“prior”inputvaluesfor
naturalhistorytransitionsusinglongitudinaldata.25–28Toreflecthet-
erogeneityinage-andtype-
specificHPVincidencebetweensettings,
aswellasnaturalimmunityfollowinginitialinfectionanduncertainty
in progression and regression of precancer, we set plausible ranges 
around these input values. We then performed repeated model sim-
ulationsintheabsenceofanyintervention,selectingasinglerandom
value from the plausible range for each uncertain parameter thereby 
creatingauniquenaturalhistoryinputparameterset.Foreachunique
parameterset,wecomputedagoodness-
of-
fitscorebysummingthe
log-
likelihoodofmodel-
projectedoutcomestorepresentthequalityof
fittocountry-
specificepidemiologicdata(e.g.age-
specificprevalence
ofoncogenicHPV;age-
specificcervicalcancerincidence).Forthepres-
ent analysis, we selected 10 input parameter sets that produced good 
fittotheepidemiologicdatafromeachcountrytouseasaformofprob-
abilisticsensitivityanalysis(SupplementalmaterialFiguresS1–S8).We
averagedthepercentreductionincancerincidenceandmortalityacross
the 10 parameter sets to arrive at average values for each of the four 
countrymodels.Becausetestperformanceandprogrammaticassump-
tionswereidenticalacrossmodelsimulations,therewereonlymodest
differencesbetweencountriesinthepercentreductionsincancerinci-
denceandmortalityattributabletoscreening.Thus,weassumedthat
thepercentreductionswouldnotbelikelytovarysubstantiallyacross
settingswithdifferentdiseaseburdens,solongasscreeningprogram
characteristicswereheldconstant.Weaveragedthepercentreductions
acrossthefourcalibratedmicrosimulationmodelsandusedtheseval-
uesasinputsintotheCERVIVACmodel.Thesereductionswereapplied
tocervicalcancerincidenceandmortalityratesandpopulationinputs
togeneratethereductionincancercasesanddeaths,aswellasshifts
incancerstagedistribution,attributabletoscreeningduringtheinter-
ventionperiod(Figure2A,B;SupplementarymaterialTablesS7andS8).
The health impact of cervical cancer treatment was used for 
DALY calculations. We used country-
specific access to radiation
therapy infrastructure as a proxy for access to treatment at any
stage, given that most women with cervical cancer present with 
regionalcancerintheabsenceoforganizedscreening.22 For coun-
trieswithnodataonradiationtherapyinfrastructure,weassumed
no current access to cancer treatment at any stage (Supplementary 
materialTableS9).Weassumedthattheproportionofwomenwith
accesstotreatmentinacountryreceivedthestage-
specificstan-
dardofcarebasedontheInternationalFederationofGynecology
andObstetrics(FIGO)guidelinesandaccordinglyhad5-
yearrelative
survival rates resembling the US Surveillance, Epidemiology, and 
End Results Program: 92% for local, 57% for regional, and 17% for 
distant cancer.28Weassumedthattheproportionofwomenwho
hadnoaccesstocancertreatmenthad5-
yearabsolutesurvivalrates
based on a linear regression of survival in the IARC SurvCan data-
base and access to radiation therapy22,29 (65% for local, 37% for 
regional,and16%fordistantcancers).Inasensitivityanalysis,we
assumed all women with cancer had access to treatment based on 
the FIGO guidelines.
2.4 | Costs
All costs were converted to 2013 US $, and we assumed that inter-
ventioncostsdidnotvarywithcoveragelevel.Forvaccination,we
assumedthepriceof$4.50perdoseforGavi-
eligiblecountriesandthe
PAHO Revolving Fund Price of $8.50 per dose for the four remaining 
countries(Bolivia,Honduras,RepublicofMoldova,andUzbekistan).
We estimated the country-
specific HPV vaccine delivery cost per
dose as previously described (Supplementary material Tables S10 and 
S11).15Forscreening-
relatedcosts,weincludedthecountry-
specific
direct medical costs associated with screening, diagnosis (if relevant), 
and treatment of precancer, as previously described (Supplementary 
material Tables S12–S14).15
Cancer treatment costs were similarly derived for each country, 
assuming stage-
specific treatment protocols based on FIGO guide-
lines (Supplementary material Tables S15 and S16).
3 | RESULTS
3.1 | Health impact
TheaggregatedhealthimpactofHPVvaccinationof10-
year-
oldgirls
andcervicalcancerscreeningofwomenaged35yearsovera10-
year
FIGURE 2 Model-
basedapproachtoquantifyingthehealthandeconomicimpactofHPVvaccination(younggirlsaged10years)and
cervicalcancerscreening(womenaged35years).(A)ToestimatethehealthandeconomicimpactofHPVvaccination,weusedtheCERVIVAC
vaccinationmodule.CERVIVACisanExcel-
basedpopulationmodelthatintegratesdiseaseburdenandpopulationstatistics;thevaccination
moduleestimatestheimpactofHPVvaccinationbasedoncountry-
specificvaccinationcosts,cancercosts,vaccineefficacy,typedistribution
ofHPV-
16/18incancer,andcancerincidenceandmortality.(B)Toestimatethehealthandeconomicimpactofcervicalcancerscreening,we
usedanindividual-
basedmicrosimulationmodelofHPVinfectionandcervicalcarcinogenesiscalibratedtofourlow-
andlower-
middle-
income
countrysettings.ThemicrosimulationmodelreflectstransitionsbetweenhealthstatesbasedonHPVgenotype,age,durationofHPVinfection
and precancer, and history of prior infection. Outputs of the microsimulation model include cancer incidence and mortality reduction by age 
andcancerstagedistributionatdetection.WeusedtheseoutputstoinformtheCERVIVACscreeningmodule,whichestimatestheimpactof
screeningbasedoncountry-
specificscreeningandtreatmentcosts,cancercosts,screeningtestperformance,prevalenceofHPVandprecancer,
andcancerincidenceandmortality.[Colourfigurecanbeviewedatwileyonlinelibrary.com]
     |  51
﻿Campos  ET CAL
(A)
(B)
 52  |    
﻿Campos  ET CAL
TABLE 1 Costs,healthoutcomes,andcost-
effectivenessofHPVvaccinationof10-
year-
oldgirlsandcervicalcancerscreeningforwomenaged35years(2017–2026)in50low-
and
lower-
middle-
incomecountries.a
Income 
tier
Number 
eligible 
(millions)
Number 
reached 
(millions)
Program 
cost 
(millions)
Program 
cost 
(millions)
CCTx 
cost 
averted 
(millions)
CCTx cost 
as % of 
program 
cost
Net cost 
(program 
- 
CCTx 
averted) 
(millions)
Cases 
averted 
(thousands)
Deaths 
averted 
(thousands)
DALYs 
averted 
(millions)
Program 
cost per 
woman 
reached
Program 
cost per 
case 
averted
Program 
cost per 
death 
averted
Program 
Cost per 
DALY 
Averted
Net 
Cost per 
DALY 
Averted
U
D
D
U
U
D
U
U
U
D
D
Vaccine
LI
112
63
$768
$643
$15
2%
$628
1732
1318
5.0
$12.14
$443
$583
$129
$126
LMI1
181
100
$1538
$1291
$222
17%
$1069
1563
1099
4.5
$15.42
$984
$1399
$287
$238
Total
293
163
$2306
$1934
$237
12%
$1697
3295
2417
9.5
$14.15
$700
$954
$204
$179
Screening
LI
61
50
$247
$207
$15
7%
$192
551
446
3.9
$4.95
$448
$553
$52
$49
LMI1
148
120
$1265
$1072
$466
43%
$606
1312
880
8.6
$10.51
$964
$1437
$124
$70
Total
209
170
$1512
$1279
$481
38%
$799
1863
1326
12.6
$8.88
$811
$1140
$102
$64
Combined
LI
173
113
$1014
$850
$29
3%
$821
2283
1764
8.9
$8.97
$444
$575
$95
$92
LMI1
329
220
$2803
$2363
$688
29%
$1675
2875
1979
13.1
$12.74
$975
$1416
$180
$128
Total
502
333
$3817
$3213
$717
22%
$2496
5158
3743
22.0
$11.46
$740
$1020
$146
$113
Abbreviations:CCTx,Cervicalcancertreatment;D,Discountedatarateof3%peryear;DALY,disabilityadjustedlifeyear;LI,low-
incomecountries(GrossNationalIncome[GNI]percapita<$1045);LMI1,
lower-
middleincomecountriestier1(GNIpercapita$1046–$2585)14; U, undiscounted.
aScreeningincludestreatmentofanywomenwithprecancerouslesionseligibleforcryotherapyorloopelectrosurgicalexcisionsurgery.
     |  53
﻿Campos  ET CAL
intervention period (2017–2026) is presented in Table1 for all 50
countries considered; results are also presented separately for India 
in Supplemental material Table S17. An HPV vaccination targeting
young girls and scaling up at a rate of 10% per year would reach an 
estimated163milliongirlsinlow-
incomeandlower-
middle-
income
tier1countries.HPVvaccinationduringa10-
yearinterventionperiod
wouldavertanestimated3.3millioncervicalcancercases,2.4million
deaths, and9.5millionDALYsoverthelifetimesofthevaccinated
cohorts.
Ascreeningprogramreachingfullscalewithinthefirst5years
of the intervention period would reach an estimated 170 million
women. Screening efforts during a 10-
year intervention period
would avert an estimated 1.9 million cervical cancer cases, 1.3
million deaths, and 12.6 million DALYs over the lifetimes of the
screened cohorts.
3.2 | Cost and cost- 
effectiveness
Total costs for the HPV vaccination program and cervical cancer
screening program, by year, are displayed in Figure 3. The total cost of 
theHPVvaccinationprogramrollingoutcoverageatarateof10%per
yearwasanestimatedUS$1.93billion(discounted)overtheinterven-
tionperiod.Duetothelimitedavailabilityofcancertreatment,particu-
larlyinlow-
incomecountries,cervicalcancertreatmentoffsetswere
relativelysmall,particularlyinlow-
incomecountries;US$237million
in cervical cancer treatment costs were averted. As a result, the net 
costofanHPVvaccinationprogramremainedhighatUS$1.70billion.
The program cost per vaccinated girl was US $14.15 (undiscounted), 
whilethenetcostperDALYavertedwasUS$179(discounted).
The total cost of a screening program for women aged 35 years, 
reaching full coverage during the first 5years of the intervention
period,was US$1.28 billion (discounted). Cancer treatment offsets
wereapproximately38%oftotalprogramcosts;thenetcostofthe
screening program was US $799 million. The program cost per woman 
reachedwasUS$8.88,andthenetcostperDALYavertedwasUS$64.
While we report the aggregated results across all countries in each 
incometier,theICERforHPVvaccinationwasbelowcountrypercap-
ita GDP in all but one country, and the ICER for screening was below 
countrypercapitaGDPinallcountries.Thus,bothHPVvaccinationof
younggirlsandcervicalcancerscreen-
and-
treatprogramsforwomen
aged35yearswereestimatedtobeverycost-
effective.
Theresultsfromthesensitivityanalysisinwhichweassumedfull
access to cancer treatment are presented in Supplementary material 
Table S18. As more cancer treatment costs were averted, the net cost 
perDALYavertedfromHPVvaccinationbecamemoreattractive.The
netcostassociatedwithscreeningbecamenegative,asthescreening
program costs were lower than the cancer treatment costs averted. As 
aresult,thenetcostperDALYavertedfromascreeningprogramwas
cost saving.
4 | DISCUSSION
Toourknowledge,thisstudyprovidesthefirstcomprehensiveesti-
mateofthecostandhealthimpactofcervicalcancerpreventionin
low-
andlower-
middle-
incomecountries,includingHPVvaccination
ofyounggirlsandonce-
in-
a-
lifetimescreeningandtreatmentofpre-
cancerforwomenofscreeningage.WefoundthatbothHPVvacci-
nationandscreeningonceinalifetimewereverycost-
effective,and
a comprehensive program could avert 5.2 million cases, 3.7 million 
deaths, and 22.0 million DALYs over the lifetimes of the interven-
tioncohortsforatotal10-
yearprogramcostofUS$3.2billion(dis-
counted). We note that the program cost per woman reached was 
higherforvaccinationthanforscreeningbecausethecostoftwovac-
cine doses and the delivery cost per dose tended to be higher than 
thecostofscreeningwitheitherVIAorHPVtesting.Whilevaccina-
tion averted more cervical cancer cases and deaths than screening
overthelifetimeoftheinterventioncohorts(despiteaslowerroll-
out
forvaccination),DALYsavertedwerehigherwithscreeningowingto
stageshiftsincancerdetectionthatleadtofeweryearslivedwith
disability(YLD).
Otherstudieshaveexaminedthecost-
effectivenessofHPVvac-
cinationinGavi-
eligiblecountriesandlow-
andmiddle-
incomecoun-
tries (LMICs).30,31OurestimatethatHPV-
16/18vaccinationisvery
cost-
effective,withacostperDALYlessthanGDPpercapita,iscon-
sistentwiththepublishedliterature.Analyseswillneedtobecontex-
tualizedtoindividualcountries—withsetting-
specificcosts,screening
algorithms, and roll-
out scenarios—for local decision making. While
wearenotawareofotherstudiesthathaveestimatedthehealthand
FIGURE 3 TotalprogramcostsforHPVvaccinationofyoung
girlsaged10yearsandonce-
in-
a-
lifetimescreeningofwomen
aged35years,2017–2026.[Colourfigurecanbeviewedat
wileyonlinelibrary.com]
 54  |    
﻿Campos  ET CAL
economic impact of cervical cancer screening aggregated across coun-
triesinLMICs,amodelingstudyfoundPaptestingandVIAtobevery
cost-
effectiveintheWHOsub-
regionsofSub-
SaharanAfrica(AfrE)
and South East Asia (SearD).32Country-
contextualizedanalyseshave
found a two-
visit screen-
and-
treat approach, with careHPV testing
(Qiagen,Gaithersburg,MD,USA;alower-
costHPVDNAtest),tobe
verycost-
effective,yieldinggreaterhealthbenefitsandabettervalue
forpublichealthdollarsthanVIAorPap.17,18
Thereareseverallimitationstothisanalysis.Intheabsenceofdata
onfuturediseasetrends,weassumedGLOBOCANestimatesofcer-
vicalcancerincidenceandmortalitywerestableoverthelifetimesof
girlsaged10yearsandwomenaged35yearsduringtheintervention
period.Werelieduponextrapolationtechniquestoestimatecountry-
specificepidemiologicandcostdata.Thecountry-
specificunitcosts
wereextrapolatedfromprimarydata,anditwasnotalwayspossible
toparsethefinancialversustheopportunitycostsfromthemultiple
primary data sources used; we assumed these generally represented 
financialcosts.Weassumedthefourcountriesthatwerenoteligible
forsupportfromGaviwouldbeabletoprocuretheHPVvaccineat
a price similar to that of the PAHO Revolving Fund, which may not 
be true for the two that are not PAHO member states. We also did 
notexplicitlyconsiderHIVburdeninthisanalysis.Ourestimatesof
vaccine impact do not account for indirect protection due to herd
immunityamongunvaccinatedgirls,andthusmayunderestimatethe
health benefits of HPV vaccination. To account for herd immunity
benefits,HPVtransmissionmodelsinformedbysexualbehaviordata
areneeded.Wehavenotexploredtheimpactofvaryingcoverage,
vaccineefficacy,screeningtestperformance,orvisitcompliancehere,
but have described elsewhere the importance of these parameters in 
estimatingthecost-
effectivenessofcervicalcancerprevention.33,34
Whileourassumptionofscale-
upto100%coverageofthetar-
getpopulationsandperfectcompliancewithvaccinationorscreening
arenotrealistic,webelievetheestimatesofcostandhealthimpact
representanupperboundontherequiredfinancialoutlays(froma
payer’sperspective)forcervicalcancerpreventioninLMICs.Asoci-
etalperspectivewouldbeneededtocaptureallcostsregardlessof
payer,includingwomen’scostsfortimeandtransportation,whichcan
besubstantialinlow-
resourcesettings.35 Due to lack of data, we have 
not included programmatic costs for infrastructural improvements,
whichmaybesubstantial.Bynotincludingtheseimportantsocietal
costs,we are likely underestimating the economic costs of cervical
cancerprevention.Ontheotherhand,becauseweassumedcancer
treatmentwasbasedonestimatedcurrentaccesstocancercarein
eachcountry—whichislowinnearlyallofthecountriesconsidered—
weunderestimatedcancertreatmentoffsetsinthebasecase;insen-
sitivityanalysis,ICERsdecreased(i.e.becamemoreattractive)when
we assumed all women with cancer had access to the standard of care. 
Furthermore,householdandproductivitylossesattributabletocer-
vicalcancerarelikelysizablebutverydifficulttoquantify.Finally,we
didnotassesstherelativecost-
effectivenessofallpossiblescreening
tests,soresultscannotbeusedtoidentifytheoptimaltest.
In 2015, US $36.4 billion in development assistance for health was 
disbursed.36Ofthis,US$10.8billionwasforHIV/AIDS,US$6.5billion
was for child and newborn health, and US $3.6 billion was for maternal 
health. While development assistance for health has increased mark-
edly since 2000,36cancerpreventionandtreatmentinLMICshasbeen
underfunded,resultinginanestimated5%ofglobalcancerresources
spent in countries hosting 80% of the global cancer burden.37 We 
estimatethatHPVvaccinationofyounggirlsandonce-
in-
a-
lifetime
screeningofwomenaged35yearswillcostapproximatelyUS$664
millionperyearatfullscalein50low-andlower-
middle-
incomecoun-
tries.BothHPVvaccinationandcervicalcancerscreeningwithtreat-
ment when needed provide very good value for public health dollars. 
Importantly,whileHPVvaccinationmayavertmorecasesanddeaths
thanscreeningatcomparablecoveragelevels,thebenefitsofvaccina-
tionwillnotberealizedfordecadestocome.Comprehensivecervical
cancerpreventionwillrequirebothHPVvaccinationand screening for 
theforeseeablefuture.Theseinterventionsprovideopportunitiesto
improveprimaryhealthcaresystemsandreducecancerdisparities.In
presentingestimatesofthecostsandhealthbenefitsassociatedwith
HPVvaccinationandcervicalcancerscreeninginthecountrieswith
thehighestburdenandtheleastaccesstopreventionopportunities,
weaimtoprovidedecisionmakerswithinformationtoaddresshealth
disparitiesandefficientlyallocateresources.
AUTHOR CONTRIBUTIONS
NC contributed to the design, planning, and conduct of the study; 
analyzeddata;anddraftedthemanuscript.MScontributedtostudy
design, data analysis, and manuscript revisions. AC contributed to 
dataanalysis,programmingoftheCERVIVACmodel,andmanuscript
revisions. KL contributed to planning of the study, data analysis, and 
manuscriptrevisions.FGanalyzeddataandcontributedtomanuscript
revisions.CRanalyzeddataandcontributedtomanuscriptrevisions.
JK contributed to the design and planning of the study, and manu-
script revisions. SR contributed to the design, planning, and conduct 
ofthestudy;analyzeddata;anddraftedthemanuscript.
ACKNOWLEDGMENTS
The authors were supported by a grant from the American Cancer 
Society (16300) (www.cancer.org). The funders had no role in the 
collection,analysis,andinterpretationofdata;inthewritingofthe
manuscript; or in the decision to submit the paper for publication.
We thank the American Cancer Society Cervical Cancer Global Cost 
ofActionAdvisoryGroupandstaffandCervicalCancerActionfor
helpfuldiscussionsonthescopeoftheresearchquestionandpolicy
optionstoconsider.
CONFLICTS OF INTERESTS
NC, MS, AC, KL, FG, CR, JK, and SR declare support from the 
American Cancer Society for the submitted work. The CERVIVAC
modelwasdevelopedincollaborationwiththePanAmericanHealth
OrganizationProVacInitiative,andinquiriesregardingthemodelcan
bemadetoProVac.Costprojectionsforindividualcountriesarenot
     |  55
﻿Campos  ET CAL
available,butratherareaggregatedbyregionorincometierasdocu-
mentedinthetext.
REFERENCES
 1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, 
Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 
[Internet],2013.Lyon,France:InternationalAgencyforResearchon
Cancer. Accessed October 20, 2014.
 2. NaudPS,Roteli-MartinsCM,DeCarvalhoNS,etal.Sustainedeffi-
cacy,immunogenicity,andsafetyoftheHPV-
16/18AS04-
adjuvanted
vaccine:Finalanalysisofalong-
termfollow-
upstudyupto9.4years
post-
vaccination.Hum Vaccin Immunother. 2014;10:2147–2162.
 3. The FUTURE II Study Group. Quadrivalent vaccine against human 
papillomavirustopreventhigh-
gradecervicallesions.N Engl J Med. 
2007;356:1915–1927.
 4. Joura EA, Giuliano AR, Iversen OE, et al. A 9-
valent HPV vaccine
againstinfectionandintraepithelialneoplasiainwomen.N Engl J Med. 
2015;372:711–723.
 5. LiN,FranceschiS,Howell-JonesR,SnijdersPJ,CliffordGM.Human
papillomavirustypedistributionin30,848invasivecervicalcancers
worldwide: Variation by geographical region, histological type and
yearofpublication.Int J Cancer. 2011;128:927–935.
 6. WorldHealthOrganization.Comprehensive Cervical Cancer Prevention 
and Control: A Healthier Future for Girls and Women. Geneva: WHO; 
2013.
 7. Bruni L, Diaz M, Barrionuevo-Rosas L, et al. Global estimates of
human papillomavirus vaccination coverage by region and income
level: A pooled analysis. Lancet Glob Health. 2016;4:e453–e463.
 8. Gavi, The Vaccine Alliance. Countries eligible for support. http:/
/
www.gavi.org/support/sustainability/countries-eligible-for-support/.
Accessed December 6, 2016.
 9. Gavi,TheVaccineAlliance.206,000moregirlstobenefitfromHPV
vaccine with GAVI Alliance support. 2014. http:/
/www.gavi.org/
library/news/press-releases/2014/206-000-more-girls-to-benefit-
from-hpv-vaccine-with-gavi-alliance-support/#sthash.Muuz1Piq.
dpuf. Accessed October 24, 2014.
10. Gavi,TheVaccineAlliance. Countries approved for support. 2016.
http:/
/www.gavi.org/results/countries-approved-for-support/.
Accessed December 6, 2016.
11. CervicalCancerAction.GlobalProgressinHPVVaccination.2016.
http:/
/www.cervicalcanceraction.org/comments/comments3.php. 
Accessed April 5, 2017.
12. Cervical Cancer Action. Global Progress in HPV DNA Testing for
Cervical Cancer Screening. 2016. http:/
/www.cervicalcanceraction.
org/comments/comments2.php. Accessed April 5, 2017.
13. CervicalCancerAction.GlobalProgressinVisualInspection(VIA)for
Cervical Cancer Screening. 2016. http:/
/www.cervicalcanceraction.
org/comments/comments.php. Accessed December 6, 2016.
14. World Bank. World development indicators. http:/
/data.world-
bank.org/data-catalog/world-development-indicators.
Accessed
September 9, 2014.
 15. Campos NG, Sharma M, Clark A, Kim JJ, Resch SC. Resources required 
forcervicalcancerpreventioninlow-
andmiddle-
Incomecountries.
PLoS ONE. 2016;11:e0164000.
 16. Campos NG, Burger EA, Sy S, et al. An updated natural history model 
ofcervicalcancer:Derivationofmodelparameters.Am J Epidemiol. 
2014;180:545–555.
17. Campos NG,TsuV,JeronimoJ, Mvundura M, Lee K, KimJJ. When
andhowoftentoscreenforcervicalcancerinthreelow-andmiddle-
income countries: A cost-
effectiveness analysis. Papillomavirus Res. 
2015;1:38–58.
18. Campos NG, Maza M, Alfaro K, et al. The comparative and cost-
effectivenessofHPV-
basedcervicalcancerscreeningalgorithmsinEl
Salvador. Int J Cancer. 2015;137:893–902.
19. PaavonenJ,NaudP,SalmeronJ,etal.Efficacyofhumanpapillomavi-
rus(HPV)-
16/18AS04-
adjuvantedvaccineagainstcervicalinfection
and precancer caused by oncogenic HPV types (PATRICIA): Final
analysisofadouble-
blind,randomisedstudyinyoungwomen.Lancet. 
2009;374:301–314.

20. DeCarvalhoN,TeixeiraJ,Roteli-MartinsCM,etal.Sustainedeffi-
cacy and immunogenicity of the HPV-
16/18 AS04-
adjuvanted
vaccine up to 7.3 years in young adult women. Vaccine. 2010;28: 
6247–6255.
21. RomanowskiB,SchwarzTF,FergusonLM,etal.Immunogenicityand
safety of the HPV-
16/18 AS04-
adjuvanted vaccine administered
asa2-
doseschedulecomparedwiththelicensed3-
doseschedule:
Resultsfromarandomizedstudy.Hum Vaccin. 2011;7:1374–1386.
22. Datta NR, Samiei M, Bodis S. Radiation therapy infrastructure and
human resources in low-
 and middle-
income countries: Present
status and projections for 2020. Int J Radiat Oncol Biol Phys. 
2014;90:971–972.
23. World Health Organization. Macroeconomics and Health: Investing 
in Health for Economic Development: Report of the Commission on 
Macroeconomics and Health. Geneva: WHO; 2001.
24. United Nations, Department of Economic and Social Affairs,
Population Division. World Population Prospects: The 2015 Revision. 
NewYork:UnitedNations;2015.
25. MunozN,MendezF,PossoH,etal.Incidence,duration,anddeter-
minants of cervical human papillomavirus infection in a cohort
of Colombian women with normal cytological results. J Infect Dis. 
2004;190:2077–2087.
26. HerreroR,HildesheimA,RodriguezAC,etal.Rationaleanddesign
of a community-
based double-
blind randomized clinical trial of
an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. Vaccine. 
2008;26:4795–4808.
 27. Sankaranarayanan R, Swaminathan R, Brenner H, et al. Cancer sur-
vivalinAfrica,Asia,andCentralAmerica:Apopulation-
basedstudy.
Lancet Oncol. 2010;11:165–173.
 28. Surveillance Epidemiology, and End Results (SEER) Program. 
SEER*Stat Database: Incidence - SEER 18 Regs Research Data +
HurricaneKatrinaImpactedLouisianaCasesNov2011Sub(1973-
2009varying)–LinkedtoCountyAttributes–TotalUS,1969–2010
Counties.AccessedNovember26,2013.
 29. Sankaranarayanan R, Swaminathan R, Lucas E. Cancer Survival in 
Africa, Asia, the Caribbean and Central America. Lyon: IARC; 2011.
30. GoldieSJ,O’SheaM,CamposNG,DiazM,SweetS,KimSY.Health
andeconomicoutcomesofHPV16,18vaccinationin72GAVI-
eligible
countries. Vaccine. 2008;26:4080–4093.
31. Jit M, Brisson M, Portnoy A, Hutubessy R. Cost-
effectiveness of
femalehumanpapillomavirusvaccinationin179countries:APRIME
modelling study. Lancet Glob Health. 2014;2:e406–e414.
32. GinsbergGM,LauerJA,ZelleS,BaetenS,BaltussenR.Costeffective-
ness of strategies to combat breast, cervical, and colorectal cancer 
insub-
SaharanAfricaandSouthEastAsia:Mathematicalmodelling
study. BMJ. 2012;344:e614.
33. CamposNG,TsuV,JeronimoJ,MvunduraM,LeeK,KimJJ.Toexpand
coverage,orincreasefrequency:Quantifyingthetradeoffsbetween
equity and efficiency facing cervical cancer screening programs in
low-
resourcesettings.Int J Cancer. 2017;140:1293–1305.
 34. Campos NG, Castle PE, Wright TC Jr, Kim JJ. Cervical cancer screen-
inginlow-
resourcesettings:Acost-
effectivenessframeworkforvalu-
ingtradeoffsbetweentestperformanceandprogramcoverage.Int J 
Cancer. 2015;137:2208–2219.
35. GoldieSJ,GaffikinL,Goldhaber-FiebertJD,etal.Cost-
effectiveness
of cervical-
cancer screening in five developing countries. N Engl J 
Med. 2005;353:2158–2168.
 36. Dieleman JL, Schneider MT, Haakenstad A, et al. Development assis-
tanceforhealth:Pasttrends,associations,andthefutureofinterna-
tionalfinancialflowsforhealth.Lancet. 2016;387:2536–2544.
 56  |    
﻿Campos  ET CAL
37. FarmerP,FrenkJ,KnaulFM,etal.Expansionofcancercareandcon-
trolincountriesoflowandmiddleincome:Acalltoaction.Lancet. 
2010;376:1186–1193.
SUPPORTING INFORMATION
AdditionalSupportingInformationmaybefoundonlineinthesupport-
inginformationtabforthisarticle.
Figure S1. Selected model output compared with empirical data (i.e. 
calibrationtargets)onage-
specificprevalenceofhigh-
riskHPVinEl
Salvador[15].
Figure S2. Selected model output compared with empirical data (i.e. 
calibration targets) on age-
specific prevalence of high-
risk HPV in
India[29].
Figure S3. Selected model output compared with empirical data (i.e. 
calibration targets) on age-
specific prevalence of high-
risk HPV in
Nicaragua[29].
Figure S4. Selected model output compared with empirical data (i.e. 
calibration targets) on age-
specific prevalence of high-
risk HPV in
Uganda[29].
Figure S5. Selected model output compared with empirical data (i.e. 
calibrationtargets)onage-
specificcancerincidenceinElSalvador[15].
Figure S6. Selected model output compared with empirical data (i.e. 
calibrationtargets)onage-
specificcancerincidenceinIndia[29].
Figure S7. Selected model output compared with empirical data (i.e. 
calibration targets) on age-
specific cancer incidence in Nicaragua
[15].
Figure S8. Selected model output compared with empirical data (i.e. 
calibrationtargets)onage-
specificcancerincidenceinUganda[29].
Table S1.Countriesincludedinthestudy,byincometier[1].
Table S2. Countries included in the study, by region.
Table S3.HPVprevalenceinputs,bycountryandagegroup[2].
Table S4. Cervical cancer incidence inputs, by country and age group 
[3].
Table S5. Cervical cancer mortality inputs, by country and age group 
[3].
Table S6. Screening test performance inputs.
Table S7.Reductioninage-
specificcervicalcancerincidenceandmor-
tality(%),byscreeningtestandageatscreening,foronce-
in-
a-
lifetime
strategies(1x).
Table S8.Cancerstagedistributionatdetection,byscreeningstrategy.a
Table S9.Country-
specificaccesstocancertreatment[11].
Table S10.PublishedHPVvaccinedeliverycostperdoseestimates
(2013 US $).a
Table S11.AverageHPVvaccinedeliverycostperdose,byincometier
(2013 US $).a
Table S12. Screening, diagnosis, and treatment of cervical intraepithe-
lialneoplasia:Proceduresandlocationofservicedelivery.
Table S13. Primary data costs, by procedure, for screening and treat-
ment of precancer (2013 US $).
Table S14. Average procedure cost for screening and treatment of pre-
cancer,byincometier(2013US$).a
Table S15. Primary data costs, by procedure, for cancer treatment 
(2013 US $).
Table S16.Averagestage-
specificcostforcancertreatment,byincome
tier(2013US$).a
Table S17.Costs,healthoutcomes,andcost-
effectivenessofHPVvac-
cinationof10-
year-
oldgirlsandcervicalcancerscreeningforwomen
aged 35 years (2017–2026) in India.
Table S18. Sensitivity analysis: Costs, health outcomes, and cost-
effectiveness of HPV vaccination of 10-
year-
old girls and cervical
cancer screening for women aged 35 years (2017–2026), with 100% 
access to cancer treatment. 
